Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 2
Abstract
Quantitative estimations of first-in-human (FIH) doses are critical for phase I clinical trials in drug development. Human pharmacokinetic (PK) prediction methods have been developed to project the human clearance (CL) and bioavailability with reasonable accuracy, which facilitates estimation of a safe yet efficacious FIH dose. However, the FIH dose estimation is still very challenging and complex. The aim of this article is to review the common approaches for FIH dose estimation with an emphasis on PK-guided estimation. We discuss 5 methods for FIH dose estimation, 17 approaches for the prediction of human CL, 6 methods for the prediction of bioavailability, and 3 tools for the prediction of PK profiles. This review may serve as a practical protocol for PK- or pharmacokinetic/pharmacodynamic-guided estimation of the FIH dose.
Authors and Affiliations
Peng Zou, Yanke Yu, Nan Zheng, Yongsheng Yang, Hayley J. Paholak, Lawrence X. Yu, Duxin Sun
Keywords
Related Articles
- EP ID EP681216
- DOI 10.1208/s12248-012-9332-y
- Views 78
- Downloads 0
Monoclonal antibody form and function: Manufacturing the right antibodies for treating drug abuse
Drug abuse continues to be a major national and worldwide problem, and effective treatment strategies are badly needed. Antibodies are promising therapies for the treatment of medical problems caused by drug abuse, with...
Measuring Endocannabinoid Hydrolysis: Refining our Tools and Understanding
Endocannabinoids (eCBs) are lipid transmitters that are released from membrane precursors in response to specific stimuli, activate cannabinoid receptors—the molecular targets of compounds produced by Cannabis sa...
Prediction of Deleterious Non-synonymous Single-Nucleotide Polymorphisms of Human Uridine Diphosphate Glucuronosyltransferase Genes
The online version of this article (doi:10.1208/s12248-009-9126-z) contains supplementary material, which is available to authorized users.
Summary Report of PQRI Workshop on Nanomaterial in Drug Products: Current Experience and Management of Potential Risks
At the Product Quality Research Institute (PQRI) Workshop held last January 14–15, 2014, participants from academia, industry, and governmental agencies involved in the development and regulation of nanomedicines...
The H2 Receptor Antagonist Nizatidine is a P-Glycoprotein Substrate: Characterization of its Intestinal Epithelial Cell Efflux Transport
The aim of this study was to elucidate the intestinal epithelial cell efflux transport processes that are involved in the intestinal transport of the H2 receptor antagonist nizatidine. The intestinal epithelial efflux tr...